• Where currently are the greatest gaps in tools, standards, or infrastructure?

2. Depth vs. Breadth

• Should the QMIN prioritize a limited number of high-impact domains (*e.g.,* therapeutic area specific needs, methodology development) for deep investment, or a broader set of activities (*e.g.,* improved adoption and integration of QM approaches across therapeutic areas)?

3. Boundaries of Activity

• What activities are most appropriate for a precompetitive network versus those better addressed within individual development programs or regulatory submissions?

• How should the QMIN define its role relative to existing efforts, including those led by FDA and external stakeholders?

B. Operating Model

1. Structure and Governance

• What governance structures would best support a multi-stakeholder network involving FDA, industry, academia, and patient groups?

• What roles should different stakeholders play in setting priorities, developing outputs, and ensuring scientific rigor?

2. Modes of Collaboration

• What mechanisms (*e.g.,* working groups, pilot projects, public workshops, shared platforms) would most effectively support the QMIN's objectives?

• How should collaboration be structured to enable both innovation and broad participation?

3. Sustainability and Incentives

• What incentives would encourage sustained participation from stakeholders?

• What funding or resourcing models (*e.g.,* public-private partnerships) should be considered?

C. Priority Use Cases

1. Selection of Use Cases

• What types of use cases are most appropriate for initial QMIN focus?

• What criteria should be used to select and evaluate use cases?

2. Demonstration of Value

• How should the QMIN's use cases be designed to demonstrate clear impact?

• What metrics (*e.g.,* reduced development time, improved decision confidence, reduced animal use) are most appropriate?

(Authority: 21 U.S.C. 355)

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–15887 Filed 8–4–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–2364]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Food and Drug Administration Advisory Committees

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Submit written comments (including recommendations) on the collection of information by September 4, 2026.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to *https://www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting ''Currently under Review—Open for Public Comments'' or by using the search function. The OMB control number for this information collection is 0910–0833. Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Kelly Covington, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 240–402–5661, *PRAStaff@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

FDA Advisory Committees

OMB Control Number 0910–0833—Extension

This information collection supports certain Food and Drug Administration (FDA, the Agency, us or we) Advisory Committee administrative activities. FDA Advisory Committees are established to advise or make recommendations on matters of public health that come before the Agency. The Federal Advisory Committee Act (5 U.S.C. App. 2 § 3, Pub. L. 92–463) (''FACA'') defines what constitutes an ''advisory committee'' under the Act and provides general procedures to follow for the operation of advisory committees. In addition, FACA is designed to ensure that the Congress and the public are kept informed with respect to the purpose, membership, and activities of advisory committees. Public advisory committee regulations in part 14 set forth requirements governing the administrative procedures to follow for the operation of advisory committees. Agency regulations in part 14, subpart A (§§ 14.1 through 14.15) identify scope of coverage, applicable definitions, and establish general provisions. The regulations in part 14, subpart B (§§ 14.20 through 14.39) set forth content and format requirements along with required schedules for submission of information. The regulations in part 14 subparts C, D, and E (§§ 14.40 through 14.95) set forth requirements governing advisory committee establishment, recordkeeping, and maintenance, respectively.

FACA does not specify the manner in which advisory committee members and staff must be appointed. (*See generally* 5 U.S.C. App. 2. *See also,* 41 CFR 102–3.105, 102–3.130(a)). FDA's regulations, however, specify that the Commissioner ''will publish one or more notices in the **Federal Register** each year requesting nominations for voting members of all existing standing advisory committees.'' (21 CFR 14.82(a)). Nominations must specify the committee for which the nominee is recommended, include a complete curriculum vitae (CV), state that the nominee is aware of the nomination and willing to serve, and state that the nominee appears to have no conflict of interest that would preclude membership. (21 CFR 14.82(c)). In an effort to promote transparency, consistent with FDA and General Services Administration (''GSA'') policy (*See,* GSA regulations encouraging agencies to ''practice openness'' and suggesting that ''agencies may wish to explore the use of the internet to post advisory committee information . . .'' 41 CFR 102–3.95(b)), and pursuant to a settlement agreement in the case *Public Citizen Foundation, Inc.* v. *Food & Drug Administration, et al.,* No. 16–cv–781 (D.D.C.), FDA is also

seeking consent from nominees for FDA to publicly post their CVs in the event they are selected to serve on an FDA advisory committee.

In the **Federal Register** of March 23, 2026 (91 FR 13852), FDA published a 60-day notice requesting public comment on the proposed collection of information. We received one comment. The comment suggests our process could be easier if we were to have more on-line tools available. They also commented that FDA should be clearer on how the information is used in decision making.

FDA appreciates the comment. FDA has established an applicant portal on its website at: *https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm* through which submissions are made to the Agency. To facilitate reporting we have established a standardized electronic format for information data elements and a separate functionality for uploading necessary documentation, such as CVs and letters of recommendation.

This data and information are made available to Agency staff to allow them to conduct reviews of nominations and coordinate follow-up with the potential candidate to explain the advisory committee process and confirm their willingness to serve. If a candidate is deemed acceptable for participation on a committee, further action is taken to appoint them to a specific advisory committee that is appropriate to their expertise and the committee's function. FDA publishes the CV of new advisory committee members on our website. FDA believes this will increase public confidence that FDA's review of advisory committee membership nominations and the subsequent selection process has been conducted thoroughly and objectively, without regard to politics or relationships with third parties. Applying this policy across all FDA advisory committees further supports FDA's goal of maintaining science as the primary determinant in Agency decision making.

FDA estimates the burden of this collection of information as follows:

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN [1] [2]

21 CFR part 14; subpart E—members of advisory committees	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
Advisory Committee Membership Nominations	407	1	407	0.25 (15 mins.)	102
Member Submission of Updated Information	359	1	359	0.25 (15 mins.)	90
Total					192

[1] There are no capital costs or operating and maintenance costs associated with this collection of information.
[2] Sums may not total due to rounding.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–15846 Filed 8–4–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA–HG–25–005: Enhancing Reuse of NHGRI Data Assets R03.

Date: August 25, 2026.

Time: 9:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Yoon-Young Jang, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 201–9155, *yoon-young.jang@nih.gov*.

Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA–NS–25–023: Pharmacological Treatments for Neuropathic Pain.

Date: September 9, 2026.

Time: 10:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Angela Monique Boutte, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–0063, *boutteam@csr.nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 31, 2026.

Margaret N. Vardanian,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–15838 Filed 8–4–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Topics in Health Services Research.

Date: September 2, 2026.

Time: 1:30 p.m. to 8:00 p.m.